Initial treatment outcome data were available for all 1574 (79%) new smear-positive TB patients and 421 (21%) retreatment smear-positive TB patients included in the 2004 survey.
Initial clinical assessment data were available for 5/7 of the children who declined to participate.
Initial CVAD placement data were available for 1341 out of 1998 patients (67%, Table 1).
Both initial and follow-up data were available in 109 patients (96 survivors and 13 non-survivors).
Five women were excluded from the initial analyses, 4 because no data were available and 1 woman was entered into the wrong trial.
One patient attended the initial visit, but no follow-up data were available.
Initial and 12-month follow-up data were available for 115 (51% of the 224) participants whose 12-month follow-ups were due on or before 31 December 2003.
All patients underwent whole-body CT examinations at the time of the initial diagnosis, and follow-up CT data were available for 33 patients, 31 of whom received corticosteroid therapy.
Of the 539 children for whom data were available from the initial visits (days 1 3), 92 (17.1%, 95% CI: 13.9% to 20.2%) were found to have HBP.
Mean ± SD parasite clearance time was 81.2 ± 35.4 hours for all patients treated with IV artesunate as first-line drug, who had an initial parasitemia levels >1% and for whom data were available (patients 2 12, 14, and 20 24), and 78.9 ± 29.5 hours for patients not infected with HIV.
